Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.
The conversation is about a user concerned about a prescribed 5 mL daily dose of 5% minoxidil for seborrheic dermatitis and hair thinning, which seems excessive compared to the typical 2 mL recommendation. The user is advised to consult their dermatologist and consider additional treatments like ketoconazole and CBD+MCT.
Oral minoxidil at 0.625mg/day caused dizziness, heart thumping, and fatigue. The user is concerned if these side effects will subside or indicate unsuitability for the medication.
Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."
The conversation is about using topical tazarotene with minoxidil for hair loss treatment. A user suggests using a lower strength than 0.025% for daily application.
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
Oral minoxidil and creatine can be used together, but it's advised to start one at a time to monitor side effects. Creatine may increase DHT levels, potentially causing more hair shedding, while minoxidil can lower blood pressure, so hydration and monitoring for dizziness are important.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
The conversation is about incorporating tretinoin into a topical minoxidil routine for better hair loss treatment. The user is considering compounded minoxidil sprays with tretinoin from brands like Keeps and Roman.
Using 0.025% tretinoin may enhance minoxidil's effects for hair loss. Users suggest starting with 0.025% and gradually increasing the concentration, and discuss combining treatments like microneedling.
The conversation discusses using minoxidil and Koshine for hair loss. It suggests applying them separately with a 5-minute gap and using Koshine on dry hair.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
A user is trying 2-deoxy-D-ribose with distilled water for hair growth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.
Oral minoxidil is generally more effective than topical minoxidil, despite higher side effect risks. Topical minoxidil can achieve higher bloodstream levels in some individuals, but effectiveness depends on conversion and scalp response.
A male with early-stage hair loss experienced severe side effects, including sexual dysfunction from finasteride and increased heart rate and fatigue from high-dose minoxidil, leading to discontinuation of both treatments. He is now relying on DHT-blocking shampoos and awaiting new treatments.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
The user experienced high liver enzyme levels, possibly due to topical finasteride or supplements, and decided to stop using finasteride while continuing minoxidil. After stopping finasteride and supplements, liver levels returned to normal, suggesting finasteride or supplements might have been the cause.
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.
The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.
Using essential oil roller bottles makes applying minoxidil easier and more convenient. Oral minoxidil has potential side effects, including heart issues, while topical application is considered safer.
The conversation is about the legitimacy and affordability of ordering a Minoxidil response test from TrichoGene, an India-based company, as an alternative to Daniel Alain. The user is seeking feedback on whether TrichoGene is a reliable option.
The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.